1. Home
  2. BOSC vs TVRD Comparison

BOSC vs TVRD Comparison

Compare BOSC & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo B.O.S. Better Online Solutions

BOSC

B.O.S. Better Online Solutions

HOLD

Current Price

$4.42

Market Cap

29.9M

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$1.87

Market Cap

27.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOSC
TVRD
Founded
1990
2017
Country
Israel
United States
Employees
N/A
12
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.9M
27.5M
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
BOSC
TVRD
Price
$4.42
$1.87
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$8.00
$29.50
AVG Volume (30 Days)
23.3K
1.2M
Earning Date
05-28-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.97
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.80
$1.50
52 Week High
$6.72
$43.65

Technical Indicators

Market Signals
Indicator
BOSC
TVRD
Relative Strength Index (RSI) 58.57 35.58
Support Level $4.50 $1.50
Resistance Level $4.58 $4.32
Average True Range (ATR) 0.09 0.24
MACD 0.02 -0.08
Stochastic Oscillator 64.58 3.65

Price Performance

Historical Comparison
BOSC
TVRD

About BOSC B.O.S. Better Online Solutions

BOS Better Online Solutions Ltd is a provider of comprehensive solutions to enterprises, comprised of services, equipment, and custom-made automatic machines. The company manages its business in three reportable divisions: the Supply Chain Solutions Division, the RFID Division, and the Intelligent Robotics Division. The majority of revenue derives from Supply Chain Solutions, which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their component-supply needs. Its geographic areas are Israel, East Asia, India, America, Europe, and the rest of the world. Geographically company derives the majority of its revenue from Israel.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: